Trials / Unknown
UnknownNCT03294343
Risk-Reducing Surgeries for Hereditary Ovarian Cancer
Risk-Reducing Surgeries of Salpingo-oophorectomy With/Without Hysterectomy for Carriers With Mutation Genes of Hereditary Ovarian Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- Lei Li · Academic / Other
- Sex
- Female
- Age
- 35 Years
- Healthy volunteers
- Accepted
Summary
Based on studies of "Inherited Susceptible Genes Among Epithelial Ovarian Cancer" (NCT03015376, clinicaltrials.gov) and "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer" (NCT03291106, clinicaltrials.gov), we provide risk-reducing surgeries of salpingo-oophorectomy with/without hysterectomy for healthy carriers with mutation genes of hereditary ovarian cancer, which is defined ovarian cancer with relevant pathogenic mutations.
Conditions
- Hereditary Breast and Ovarian Cancer Syndrome
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Ovariectomy
- Hysterectomy
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | salpingo-oophorectomy only by laparoscopy | Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants. |
| PROCEDURE | salpingo-oophorectomy with hysterectomy by laparoscopy | Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants. |
| OTHER | Follow-up | Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2022-09-01
- Completion
- 2023-09-01
- First posted
- 2017-09-27
- Last updated
- 2017-12-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03294343. Inclusion in this directory is not an endorsement.